This is the authors' abstract. We don't add key points for this paper.
Background: The current literature on female breast cancer screening is largely focused on the health outcomes that result from screening. There is comparatively little data on the cost-effectiveness of the screening. Methods: This systematic review sought to identify all studies published within the last 10 years that analyzed the cost-effectiveness of mammography-based female breast cancer screening policies in Canada. Results: Seven studies were included, and four were applicable to the average-risk Canadian women. Triennial screening for average-risk women aged 50–69 years was the most cost-effective in terms of cost per QALY. The use of MRI with mammography for women with the BRCA1/2 mutation was cost-effective, while annual mammography-based screening for women with dense breasts was cost-ineffective. Conclusion: Analyses of the cost-effectiveness of mammography-based screening within Canadian populations are few in numbers and have heterogeneous methodologies. The existing data suggest that Canada’s current screening policy to screen average-risk women aged 50–74 years, biennially or triennially is cost-effective.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Tahir et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: